Table 3. Multivariate survival analysis of the discovery and the validation sets.
| HR (95%) CI | P | |
|---|---|---|
|
5-year CSS in the discovery seta | ||
| CIMP-N | 0.47 (0.28–0.78) | 0.004 |
| CIMP-P1 | Reference | − |
| CIMP-P2 | 0.28 (0.07–1.22) | 0.090 |
|
5-year RFS in the validation setb | ||
| CIMP-N | 0.50 (0.29–0.88) | 0.015 |
| CIMP-P1 | Reference | − |
| CIMP-P2 | 0.21 (0.05–0.92) | 0.038 |
Abbreviations: CI=confidence interval; CSS=cancer-specific survival; HR=hazard ratio; RFS=relapse-free survival.
a
Adjusted for stage, differentiation and chemotherapy status.
b
Adjusted for stage (III vs II, high risk) and differentiation.